Hostname: page-component-78c5997874-8bhkd Total loading time: 0 Render date: 2024-11-15T04:15:26.494Z Has data issue: false hasContentIssue false

The Role of Vaccine Research and Development in the Scientific Development of Middle-Income Countries

Published online by Cambridge University Press:  14 October 2009

Adolfo Martínez-Palomo
Affiliation:
Center for Research and Advanced Studies, Mexico
Malaquías López-Cervantes
Affiliation:
National Institute of Public Health, Mexico
Phyllis Freeman
Affiliation:
University of Massachusetts, Boston

Abstract

As a new global strategy for improving public health, the Children's Vaccine Initiative implicitly raises, once again, the question of the role of science in developing countries. If there are to be new and improved vaccines, better delivery systems, and simplified immunization schedules, there must be substantial analysis, laboratory activity, and fieldwork to ensure that the new products are ready for effective use. In the context of these requirements, this paper reviews the possibilities for vaccine research and development in middle-income countries and the benefits in terms of fostering socioeconomic development through integrated scientific health research.

Type
Special Section: Vaccines and Public Health: Assessing Technologies and Public Policies
Copyright
Copyright © Cambridge University Press 1994

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Arno, P. S., & Feiden, K. L.Against the odds: The story of AIDS drug development, politics and profits. New York: Harper Collins, 1992.Google Scholar
2.Comision Mexicana de Investigacion en Salud (COMISA). Objetivos y organizacion. Mexico, 1991.Google Scholar
3.Evans, J. R., Lashman-Hall, K., & Warford, J.Health care in the developing world: Problems of scarcity and choice. New England Journal of Medicine, 1981, 305, 1117–27.CrossRefGoogle ScholarPubMed
4.Evans, P. Paper presented before the Children's Vaccine Initiative Management Advisory Committee, Meech Lake, Canada, May 21–22, 1992.Google Scholar
5.Freeman, P., & Robbins, A.The elusive promise of vaccines. American Prospect, Winter, 1992.Google Scholar
6.Frenk, J., Bobadilla, J. L., Sepulveda, J., et al. Health transition in middle income countries: New challenges for health care. Health Policy Planning, 1989, 4, 2939.CrossRefGoogle Scholar
7.Homma, A., & Knouss, R.The transfer of vaccine technology to developing countries: The Latin American experience. International Journal of Technology Assessment in Health Care, 1994, 10, 4754.CrossRefGoogle ScholarPubMed
8.International Commission on Health Research for Development. Health research: Essential link to equity in development. New York: Oxford University Press, 1990.Google Scholar
9.Markowitz, L. E., Sepulveda, J., Diaz-Ortega, J. L., et al. Immunization of six-month-old infants with different doses of E-Z and Schwarz measles vaccines. New England Journal of Medicine, 1990, 322, 580–87.CrossRefGoogle Scholar
10.Martmez-Palomo, A.Science for the third world: An inside view. Perspectives in Biology and Medicine, 1987, 30, 546–57.CrossRefGoogle Scholar
11. Pan American Health Organization. Meeting on cholera vaccines, Washington DC, May 1991.Google Scholar
12.Robbins, A.New vaccine products for the third world. Letter to the editor. Lancet, 1989, 679.CrossRefGoogle Scholar
13.Robbins, A., & Freeman, P.Obstacles to developing vaccines for the Third World. Scientific American, 1988, 126–33.CrossRefGoogle ScholarPubMed
14.United Nations Children's Fund. Children's vaccine initiative: The state of the world's children. 1992, 50.Google Scholar